SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001576885-23-000008
Filing Date
2023-03-15
Accepted
2023-03-15 16:12:31
Documents
13
Period of Report
2023-03-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abos-20230309.htm   iXBRL 8-K 41444
2 EX-3.1 abos-20230309xexx31.htm EX-3.1 181062
  Complete submission text file 0001576885-23-000008.txt   404415

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20230309.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20230309_lab.xml EX-101.LAB 25832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20230309_pre.xml EX-101.PRE 13576
7 EXTRACTED XBRL INSTANCE DOCUMENT abos-20230309_htm.xml XML 12178
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 23735292
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences